Robert E Goldsby

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Surviving childhood cancer; now what? Controversies regarding long-term follow-up
    Robert E Goldsby
    Pediatric Oncology, UCSF Box 0106, San Francisco, CA 94143-0106, USA
    Pediatr Blood Cancer 43:211-4. 2004
  2. ncbi Surviving childhood cancer: the impact on life
    Robert E Goldsby
    Division of Pediatric Hematology Oncology, University of California, San Francisco, USA
    Paediatr Drugs 8:71-84. 2006
  3. ncbi Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
    Robert E Goldsby
    UCSF Pediatric Oncology, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143 0106, USA
    J Clin Oncol 28:324-31. 2010
  4. ncbi Survivors of childhood cancer have increased risk of gastrointestinal complications later in life
    Robert Goldsby
    Pediatric Hematology Oncology, UCSF Benioff Children s Hospital, San Francisco, California, USA
    Gastroenterology 140:1464-71.e1. 2011
  5. ncbi Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)
    Paul A Fitzgerald
    Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
    Ann N Y Acad Sci 1073:465-90. 2006
  6. ncbi Survival after recurrence of osteosarcoma: a 20-year experience at a single institution
    Brian D Crompton
    Department of Pediatrics, UCSF Children's Hospital, San Francisco, California 94143-0106, USA
    Pediatr Blood Cancer 47:255-9. 2006
  7. ncbi Receptor imaging of pediatric tumors: clinical practice and new developments
    Heike E Daldrup-Link
    Department of Radiology, University of California at San Francisco, San Francisco, CA 94131, USA
    Pediatr Radiol 38:1154-61. 2008
  8. ncbi Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Lars M Wagner
    Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Cancer Res 10:840-8. 2004
  9. ncbi Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis
    Ranga N Venkatesan
    Department of Pathology, University of Washington, Seattle, WA 98195 7705, USA
    Mol Cell Biol 27:7669-82. 2007

Collaborators

Detail Information

Publications9

  1. ncbi Surviving childhood cancer; now what? Controversies regarding long-term follow-up
    Robert E Goldsby
    Pediatric Oncology, UCSF Box 0106, San Francisco, CA 94143-0106, USA
    Pediatr Blood Cancer 43:211-4. 2004
  2. ncbi Surviving childhood cancer: the impact on life
    Robert E Goldsby
    Division of Pediatric Hematology Oncology, University of California, San Francisco, USA
    Paediatr Drugs 8:71-84. 2006
    ..Guidelines for long-term follow-up have been established and are available to help facilitate appropriate monitoring of and care for potential late effects...
  3. ncbi Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
    Robert E Goldsby
    UCSF Pediatric Oncology, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143 0106, USA
    J Clin Oncol 28:324-31. 2010
    ..Little is known about the incidence and severity of late-occurring neurologic sequelae in ALL survivors. Data were analyzed to determine the incidence of adverse long-term neurologic outcomes and treatment-related risk factors...
  4. ncbi Survivors of childhood cancer have increased risk of gastrointestinal complications later in life
    Robert Goldsby
    Pediatric Hematology Oncology, UCSF Benioff Children s Hospital, San Francisco, California, USA
    Gastroenterology 140:1464-71.e1. 2011
    ..However, the long-term GI consequences have not been extensively studied. We evaluated the incidence of long-term GI outcomes and identified treatment-related risk factors...
  5. ncbi Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)
    Paul A Fitzgerald
    Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
    Ann N Y Acad Sci 1073:465-90. 2006
    ..For patients with metastatic PHEO or PGL, who have good *I-MIBG uptake on diagnostic scanning, high-dose 131I-MIBG therapy was effective in producing a sustained CR, PR, or SD in 67% of patients, with tolerable toxicity...
  6. ncbi Survival after recurrence of osteosarcoma: a 20-year experience at a single institution
    Brian D Crompton
    Department of Pediatrics, UCSF Children's Hospital, San Francisco, California 94143-0106, USA
    Pediatr Blood Cancer 47:255-9. 2006
    ..Chemotherapy and time to first recurrence were unrelated to survival after relapse in this study. Complete surgical removal of metastatic disease may be important for long-term survival...
  7. ncbi Receptor imaging of pediatric tumors: clinical practice and new developments
    Heike E Daldrup-Link
    Department of Radiology, University of California at San Francisco, San Francisco, CA 94131, USA
    Pediatr Radiol 38:1154-61. 2008
    ....
  8. ncbi Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Lars M Wagner
    Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Cancer Res 10:840-8. 2004
    ..The purpose is to estimate the maximum-tolerated dose (MTD) of temozolomide and irinotecan given on a protracted schedule in 28-day courses to pediatric patients with refractory solid tumors...
  9. ncbi Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis
    Ranga N Venkatesan
    Department of Pathology, University of Washington, Seattle, WA 98195 7705, USA
    Mol Cell Biol 27:7669-82. 2007
    ....